(19)
(11) EP 2 363 404 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
07.12.2016 Bulletin 2016/49

(45) Mention of the grant of the patent:
07.09.2016 Bulletin 2016/36

(21) Application number: 10184938.8

(22) Date of filing: 23.10.2002
(51) International Patent Classification (IPC): 
C07H 21/04(2006.01)
C07K 16/00(2006.01)
G01N 33/53(2006.01)
C07K 16/30(2006.01)
 C12N 5/12(2006.01)
A61K 39/395(2006.01)
A61K 51/10(2006.01)

(54)

PSMA antibodies

PSMA Antikörper

Anticorps contre le PSMA

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 23.10.2001 US 335215 P
07.03.2002 US 362747 P
20.09.2002 US 412618 P

(43) Date of publication of application:
07.09.2011 Bulletin 2011/36

(60) Divisional application:
16187305.4

(62) Application number of the earlier application in accordance with Art. 76 EPC:
02802198.8 / 1448588

(73) Proprietors:
  • PSMA Development Company L.L.C.
    New York, NY 10007 (US)
  • Amgen Fremont Inc.
    Thousand Oaks, CA 91320-1799 (US)

(72) Inventors:
  • Maddon, Paul, J.
    Scarsdale, NY 10583 (US)
  • Donovan Gerald
    Kittery, ME 03904 (US)
  • Olson, William
    Yorktown Heights, NY 10598 (US)
  • Schulke, Norbert
    East Walpole, MA 02032 (US)
  • Gardner, Jason
    Wayne, PA 19087 (US)
  • Ma, Dangshe
    Millwood NY 10546 (US)

(74) Representative: Jump, Timothy John Simon et al
Venner Shipley LLP 200 Aldersgate
London EC1A 4HD
London EC1A 4HD (GB)


(56) References cited: : 
WO-A-01/09192
   
  • DONOVAN G P ET AL: "ANTIBODY AND VACCINE THERAPIES TARGETING PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA)", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, US, vol. 42, 24 March 2001 (2001-03-24), page 818, XP001204629, ISSN: 0197-016X
  • HOLMES E H: "PSMA specific antibodies and their diagnostic and therapeutic use", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 10, no. 3, March 2001 (2001-03), pages 511-519, XP002988381, ISSN: 1354-3784
  • LIU H ET AL: "MONOCLONAL ANTIBODIES TO THE EXTRACELLULAR DOMAIN OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN ALSO REACT WITH TUMOR VASCULAR ENDOTHELIUM", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 17, 1 September 1997 (1997-09-01), pages 3629-3634, XP001080132, ISSN: 0008-5472
  • GONG M C ET AL: "Prostate-specific membrane antigen (PMSA)-specific monoclonal antibodies in the treatment of prostate and other cancers", CANCER AND METASTASIS REVIEWS, KLUWER ACADEMIC PUBLISHERS, DORDRECHT, NL, vol. 18, no. 4, 1999, pages 483-490, XP002982445, ISSN: 0167-7659
  • SMITH-JONES P M ET AL: "In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, no. 18, 15 September 2000 (2000-09-15), pages 5237-5243, XP002327842, ISSN: 0008-5472
  • LAPIDUS RENA G ET AL: "Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 45, no. 4, 1 December 2000 (2000-12-01), pages 350-354, XP009026666, ISSN: 0270-4137
  • TINO WILLIAM T ET AL: "Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA)", HYBRIDOMA, vol. 19, no. 3, June 2000 (2000-06), pages 249-257, XP002397386, ISSN: 0272-457X
  • SCHULKE N ET AL: "The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 100, no. 22, 28 October 2003 (2003-10-28), pages 12590-12595, XP002323660, ISSN: 0027-8424
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).